



FARAPOINT™
Pulsed Field Ablation Catheter

ADVANTAGE AF CTI Subanalysis

**Boston
Scientific**
Advancing science for life™



How does pulsed field compare to radiofrequency for CTI ablation to treat typical atrial flutter?

Result: FARAPOINT™ Pulsed Field Ablation (PFA) Catheter demonstrated similar safety and effectiveness to RFA, while enabling significantly greater procedural predictability

Background:


Typical atrial flutter (AFL) is common in AFib patients and is treated with cavotricuspid isthmus (CTI) ablation. The ADVANTAGE AF CTI Subanalysis compared the safety and effectiveness of pulsed field ablation (PFA) to radiofrequency ablation (RFA)—the standard of care—for CTI ablation

Key facts:


- All patients received pulmonary vein isolation (PVI) and posterior wall ablation (PWA) with the FARAWAVE™ Pulsed Field Ablation (PFA) Catheter
- At operator discretion, patients were additionally treated for AFL with adjunctive CTI ablation using either:
 - RFA in Phase I (n=50, 19%)
 - FARAPOINT PFA in Phase II (n=141, 55%)

SAFETY ENDPOINT: FARAPOINT PFA demonstrated safety outcomes comparable to RFA

Cumulative incidence of primary safety events (p=ns)




Prophylactic IV nitroglycerin protocol during CTI ablation





The safety endpoint was calculated as the rate of predefined safety events: myocardial infarction, stroke, transient ischemic attack, thromboembolism, pulmonary edema, unresolved phrenic nerve palsy/paresis, serious vascular access complications, heart block, GI disorders occurring within 7 days of the index procedure, cardiac tamponade/perforation or pericarditis, or other PFA system/procedure related cardiovascular or pulmonary adverse events within 30 days of the index procedure, and pulmonary vein stenosis or atrio-esophageal fistula occurring prior to the 1-year follow-up. Mortality (within 7 days of procedure in Phase I and within 30 days of procedure in Phase II) was also included in the primary safety endpoint.

EFFECTIVENESS DATA: FARAPPOINT PFA resulted in 97.9% freedom from AFL recurrence at 1 year — nearly equivalent to RFA



RELIABILITY: FARAPPOINT PFA delivered significantly greater predictability in number of CTI applications and total procedure times vs RFA



Boston Scientific
Advancing science for life™

Read the full HRS abstract [here](#)

1. Based on an analysis of variance in the number of CTI applications and total procedure times in the ADVANTAGE AF trial

2. Reddy, VY, et al., 2025. Focal Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: A sub-study across Phase I and Phase II of the Pivotal ADVANTAGE AF Trial. Presented at HRS.

CAUTION: Investigational device. Limited by federal (or US) law to investigational use only. Not available for sale.

© 2025 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are the property of their respective owners. EP- 2228605-AA

Cardiology
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

Medical Professionals:
1.800.CARDIAC (227.3422)
Customer Service:
1.888.272.1001